Why the study?
Does dibutyryl cyclic AMP affect vulnerability to ventricular fibrillation in the isolated perfused rat heart?
Does dibutyryl cyclic AMP affect vulnerability to ventricular fibrillation in the isolated perfused rat heart?
High doses of dibutyryl cyclic AMP decrease the ventricular fibrillation threshold and increase the vulnerable period in isolated rat hearts, supporting the role of cAMP in catecholamine-mediated arrhythmogenesis.
Supports cAMP in VF vulnerability in rat hearts; leaves open in vivo and clinical relevance.
Ventricular fibrillation threshold and vulnerable period were measured in the isolated perfused rat heart to assess the influence of dibutyryl cyclic AMP on ventricular vulnerability. Doses of dibutyryl cyclic AMP of 0.6-1.6 mumol/min caused an increase in coronary flow but had no effect on vulnerability, whereas doses of 2.6-4.2 mumol/min resulted in an increase in coronary flow, a decrease in VF threshold, and an increase in the width of the vulnerable period. These experiments support the concept of a local myocardial action of catecholamines, mediated by cyclic AMP, whereby vulnerability to ventricular fibrillation is increased.
No takes yet. Share an insight, caveat, or question.
Lubbe et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: